Where trauma research is heading in 2026
A brief map of the questions the field is actively working on — and the ones it is not yet ready to answer.
Precision matching
Precision matching — figuring out which patients respond best to which protocols — has moved from aspiration to active trial design. Predictors are still noisy, but symptom profile, dissociation severity, early alliance ratings, and pre-treatment cognitive style all carry signal. Machine-learning approaches applied to routine outcome data are producing initial matching algorithms; whether they generalize beyond the datasets they were trained on remains open.
Pharmacological augmentation
The MDMA-assisted therapy story is more complicated in 2026 than it was in 2023. The FDA declined approval in 2024, citing trial design and safety concerns, and further trials are underway with revised protocols. Ketamine remains available off-label for treatment-resistant depression and, in some clinics, for PTSD; the trauma-specific evidence base is smaller and less consistent than for depression. Propranolol reconsolidation blockade and hydrocortisone augmentation each have small but interesting literatures worth tracking.
Delivery innovation
Brief protocols, group formats, and digital-first approaches have expanded reach, particularly in humanitarian and low-resource settings. Written Exposure Therapy's five-session structure is showing non-inferiority to longer protocols in several trials. Group CPT and group CBT for PTSD have moderate evidence. App-delivered and guided-self-help programs generally produce smaller effect sizes than gold-standard individual therapy, but the reach-versus-depth tradeoff is often the right one at population scale.
Neurobiological targets
Interest in glucocorticoid signaling, endocannabinoid function, and inflammation as trauma-relevant targets has grown. None of these has produced a first-line intervention, but they are shaping how researchers think about persistent symptoms in patients who do not respond to standard protocols.
Open questions
What the field is not yet ready to answer:
- Whether complex trauma has a distinct optimal protocol, or whether it is best served by sequenced application of existing tools.
- Whether stabilization phases can be shortened without cost, and for whom.
- How much of the treatment effect is method-specific versus common-factor.
- Whether large-scale digital interventions can maintain effect at scale, or whether they degrade in real-world deployment.
These are the honest open questions. Clinicians should hold the current evidence base firmly and hold the emerging claims loosely.